ArticleCureus2025
Frequency of Anemia and Iron Deficiency in Ulcerative Colitis Patients in Clinical Remission as per the Patient-Reported Outcome (PRO-2) Score.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Mechanisms Underlying the Higher Prevalence of Anemia in Crohn's Disease Compared with Ulcerative Colitis: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Probiotics for ulcerative colitis: mechanisms, therapeutic advances, and emerging strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Iron deficiency anemia (IDA) is commonly present in patients with ulcerative colitis (UC) due to chronic blood loss, malabsorption, and chronic inflammation. Despite advances in the management of UC, the prevalence and clinical impact of IDA remain significant, potentially affecting disease progression, quality of life, and therapeutic response. Given the complex interplay between mucosal inflammation and systemic manifestations, early detection and optimal management of IDA in UC are crucial for improving patient outcomes. This study aimed to determine the prevalence, clinical characteristics, and treatment patterns of IDA in UC patients presenting to tertiary care centers in Karachi, Pakistan. Methodology This cross-sectional study was conducted in the Medical and Gastroenterology Department of Dr Ruth KM Pfau Civil Hospital Karachi and OMI Hospital from February 2024 and June 2025. Using non-parametric convenience sampling, adult patients (≥18 years) with a confirmed diagnosis of UC, based on clinical, endoscopic, and histopathological criteria, were enrolled consecutively. Data regarding demographics, duration and extent of disease, clinical activity (using the Patient-Reported Outcome (PRO-2) and Mayo scores), laboratory parameters (hemoglobin, serum ferritin, transferrin saturation, C-reactive protein), and treatment history were collected. IDA was defined as hemoglobin below the normal reference with evidence of depleted iron stores. Patients with other causes of anemia were excluded. Descriptive and inferential statistics were used to analyze the prevalence of IDA. Results In total, 216 patients met the inclusion criteria. The prevalence of IDA was found to be 76.9% among the study cohort. Of these, 27.8% were anemic with iron deficiency, 30.6% had anaemia of chronic inflammation with iron deficiency, and 18.5% had anemia of chronic inflammation without iron deficiency. Overall, 16.7% were non-anemic with iron deficiency, while 6.5% were non-anemic with adequate iron. Anemia was more prevalent in males compared to females. Conclusions IDA was a prevalent and under-recognized complication in patients with UC in the studied population. It was associated with greater disease activity and extent, yet remains inadequately managed in clinical practice. Proactive screening and timely initiation of appropriate iron replacement, particularly intravenous formulations, are recommended to optimize clinical outcomes, enhance quality of life, and support disease remission in UC. Future studies should explore barriers to optimal anemia management and evaluate the long-term benefits of integrated care approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.